Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19894001 | 0.98 | PDPK1 (0.47) | PDPK1ADORA2AADORA1MEN1LMNA | |
| SCHEMBL23093262 | 0.83 | ERN1 (0.44) | PDPK1ADORA2AADORA1CYP2A6RAB9A | |
| SCHEMBL29658199 | 0.83 | ERN1 (0.44) | PDPK1ADORA2AADORA1CYP2A6RAB9A | |
| SCHEMBL8030413 | 0.82 | PDPK1 (0.48) | PDPK1ADORA2AADORA1CYP2A6RAB9A | |
| SCHEMBL5692672 | 0.80 | PDPK1 (0.64) | PDPK1ADORA2AADORA1CYP2A6RAB9A | |
| SCHEMBL23108267 | 0.80 | CA1 (0.46) | PDPK1MEN1KMT2ATDP1CYP2A6 | |
| SCHEMBL13351467 | 0.79 | PDPK1 (0.46) | PDPK1ADORA2AADORA1CYP2A6RAB9A | |
| SCHEMBL1951149 | 0.78 | PDPK1 (0.61) | PDPK1ADORA2AADORA1CYP2A6RAB9A | |
| SCHEMBL13318677 | 0.78 | PDPK1 (0.44) | PDPK1ADORA2AADORA1MEN1LMNA | |
| SCHEMBL27738959 | 0.78 | PDPK1 (0.49) | PDPK1ADORA2AADORA1KMT2ACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105457086-A | Method for processing titanium dioxide nanotubes through rhodium complexes | UNIV GUANGXI CHINESE MEDICINE | 2016-04-06 | — | — | CN | claimed |
| US-20250268869-A1 | METHODS OF USING A (THIAZOLYL)BENZENESULFONAMIDE DERIVATIVE | CYTEIR THERAPEUTICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2023211945-A1 | METHODS OF USING A (THIAZOLYL)BENZENESULFONAMIDE DERIVATIVE | CYTEIR THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-110590697-B | Structure, preparation and application of 2-thiazole formaldehyde-benzene Schiff base | 齐鲁工业大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-110590697-B | Structure, preparation and application of 2-thiazole formaldehyde-benzene Schiff base | 齐鲁工业大学 | 2022-09-30 | — | — | CN | disclosed |
| US-20220259198-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1392687-A1 | 1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030109539-A1 | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-12 | — | — | US | disclosed |
| WO-2002083673-A1 | 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| CN-1275909-A | In-modulators | AKZO NOBEL NV (NL) | 2000-12-06 | — | — | CN | disclosed |
| EP-1035843-A2 | I h?-MODULATORS | Akzo Nobel N.V. (NL) | 2000-09-20 | — | — | EP | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| WO-1999018941-A2 | Ih-MODULATORS | AKZO NOBEL N.V. (NL) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247988-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | PDPK1 1842/4885ADORA2A 4205/4885ADORA1 4450/4885 |
| US-20220259198-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | PDPK1 1842/4885ADORA2A 4205/4885ADORA1 4450/4885 |
| US-20030109539-A1 | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, GPR4, GPR174 | PDPK1 1549/4885ADORA2A 584/4885ADORA1 117/4885 |
| US-20250268869-A1 | METHODS OF USING A (THIAZOLYL)BENZENESULFONAMIDE DERIVATIVE | HTT, NLN, SLC16A1 | PDPK1 1580/4885ADORA2A 2968/4885ADORA1 3742/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | PDPK1 1842/4885ADORA2A 4205/4885ADORA1 4450/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | PDPK1 1216/4885ADORA2A 71/4885ADORA1 229/4885 |
| US-11932636-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | PDPK1 1842/4885ADORA2A 4205/4885ADORA1 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.